Oncocyte Corp Files 8-K: Board & Executive Changes
Ticker: IMDX · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1642380
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
TL;DR
Oncocyte Corp shakes up board and exec pay - filing details changes.
AI Summary
On June 17, 2024, Oncocyte Corporation filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the departure of certain officers and directors, alongside the election of new directors and adjustments to compensatory arrangements for key executives. Specific details regarding the individuals involved and the financial implications of these changes are outlined within the report.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty about future strategy and performance.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- June 17, 2024 (date) — Date of Report
FAQ
Who are the specific directors or officers that have departed from Oncocyte Corporation?
The filing indicates the departure of certain officers and directors, but specific names are not provided in the provided text snippet.
Were there any new directors elected to the Oncocyte Corporation board?
Yes, the filing states the election of new directors to the Oncocyte Corporation board.
What specific changes were made to the compensatory arrangements of certain officers?
The filing mentions adjustments to compensatory arrangements for key executives, but the exact nature of these adjustments is not detailed in the provided text.
What is the primary purpose of this 8-K filing for Oncocyte Corporation?
The primary purpose of this 8-K filing is to report current information regarding the departure of directors or certain officers, election of directors, and compensatory arrangements of certain officers.
What is Oncocyte Corporation's state of incorporation and fiscal year end?
Oncocyte Corporation is incorporated in California and its fiscal year ends on December 31.
Filing Stats: 1,127 words · 5 min read · ~4 pages · Grade level 11.3 · Accepted 2024-06-17 16:10:27
Key Financial Figures
- $325,000 — eceive an initial annual base salary of $325,000 (such annual base salary, as may be adj
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex99-1.htm (EX-99.1) — 18KB
- 0001493152-24-024108.txt ( ) — 237KB
- ocx-20240617.xsd (EX-101.SCH) — 3KB
- ocx-20240617_lab.xml (EX-101.LAB) — 33KB
- ocx-20240617_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCOCYTE CORPORATION Date: June 17, 2024 By: /s/ Joshua Riggs Joshua Riggs President and Chief Executive Officer